drugset / Trial / NCT00000159

Sorbinil Retinopathy Trial (SRT)

NCT00000159 ↗

Phase 3 Completed National Eye Institute (NEI)
RandomizedDouble-blindTreatment

Summary

To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.

Timeline

Start
1983-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorbinil Small molecule 250 mg —